ReviewCurrent treatment options in oncology2021
Cardiovascular Toxicities of Androgen Deprivation Therapy.
Review in Current treatment options in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Impact of androgen deprivation therapy and androgen receptor pathway inhibitors on cardiac structure and function evaluated by echocardiography in males with prostate cancer: a systematic review and meta-analysis.International urology and nephrology · 2026Pooled it
- The influence of sodium-glucose co-transporter-2 inhibitors on the risk of cancer therapy-related cardiac dysfunction: A meta-analysis.Biomolecules & biomedicine · 2025Pooled it
- A systematic review and meta-analysis of cardiovascular disease risk with degarelix and GnRH agonists in prostate cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Pooled it
- Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201).Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Cardiovascular Complications Associated with Uro-Oncology Treatments-A Primer for the Clinician.Diagnostics (Basel, Switzerland) · 2026Review
- Androgen-Modulating Drugs and Severe Complications After ST-Elevation Myocardial Infarction.JAMA network open · 2026Article
- Article
- Healthcare Management in Cardio-Oncology, Clinical Strategies and Future Perspectives: A Narrative Review.Healthcare (Basel, Switzerland) · 2025Review
- Potential New Applications of Sodium-Glucose Cotransporter-2 Inhibitors Across the Continuum of Cancer-Related Cardiovascular Toxicity.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Comorbidities And Reducing InEquitieS (CARES): Feasibility of self-monitoring and community health worker support in management of comorbidities among Black breast and prostate cancer patients.Contemporary clinical trials communications · 2025Article
- Androgen Signaling in Prostate Cancer: When a Friend Turns Foe.Endocrine, metabolic & immune disorders drug targets · 2025Review
- Adverse event profile differences among long-acting gonadotropin-releasing hormone analogs: A real-world, pharmacovigilance study.PloS one · 2025Article
- Treatment-related Hypertension as a Prognostic Factor for De Novo Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Real-world Evidence Study.European urology open science · 2025Article
- A comprehensive review on the effects of sex hormones on chemotherapy-induced cardiotoxicity: are they lucrative or unprofitable?Cardio-oncology (London, England) · 2024Review
- The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer.Medicina (Kaunas, Lithuania) · 2024Review
- Health Literacy, Individual and Community Engagement, and Cardiovascular Risks and Disparities:JACC. CardioOncology · 2024Review
- Social Determinants of Health Mediate Racial Disparities in Cardiovascular Disease in Men With Prostate Cancer.JACC. CardioOncology · 2024Article
- Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood.Medicina (Kaunas, Lithuania) · 2023Review
- Metabolic and cardiovascular disease risk for Zimbabwean men with prostate cancer receiving long-term androgen deprivation therapy.Research square · 2023Article
- Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan.Prostate cancer and prostatic diseases · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
opinion statementProstate cancer is the second leading cause of cancer death in men, and cardiovascular disease is the number one cause of death in patients with prostate cancer. Androgen deprivation therapy, the cornerstone of prostate cancer treatment, has been associated with adverse cardiovascular events. Emerging data supports decreased cardiovascular risk of gonadotropin releasing hormone (GnRH) antagonists compared to agonists. Ongoing clinical trials are assessing the relative safety of different modalities of androgen deprivation therapy. Racial disparities in cardiovascular outcomes in prostate cancer patients are starting to be explored. An intriguing inquiry connects androgen deprivation therapy with reduced risk of COVID-19 infection susceptibility and severity. Recognition of the cardiotoxicity of androgen deprivation therapy and aggressive risk factor modification are crucial for optimal patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.